A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

Bausch + Lomb

Status and phase: Withdrawn; Phase 2

Conditions: Allergic Conjunctivitis

Treatments: Drug: Ketotifen/vasoconstrictor

Study type: Interventional

Funder types: Industry

Identifiers

NCT00375596

C-02-06-001

Details and patient eligibility

About

This study will evaluate the safety and efficacy of a new allergy medication

Full description

Study withdrawn prior to determining study details

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be at least 6 years of age, of any race, or either gender.
• Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months.
• Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart.
• Positive bilateral CAC reaction at Visit 1 & 2.

Exclusion criteria

• Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components.
• Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
• Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit